All cancers - An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies
The purpose of this study is to determine whether Nivolumab is an effective treatment for advanced or metastatic cancer. The study will evaluate the clinical benefit rate of Nivolumab in subjects at 16 weeks from enrollment. Various advanced or metastatic tumor types are eligible for enrollment. Subjects must have received prior standard of care treatment for their cancer before enrollment.